• Je něco špatně v tomto záznamu ?

Dexamethasone accelerates degradation of aryl hydrocarbon receptor (AHR) and suppresses CYP1A1 induction in placental JEG-3 cell line

L. Stejskalova, A. Rulcova, R. Vrzal, Z. Dvorak, P. Pavek,

. 2013 ; 223 (2) : 183-91.

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc14050788

The JEG-3 choriocarcinoma cell line has been proposed as a model cell line of human placental trophoblast for induction studies via aryl hydrocarbon receptor (AHR). We examined whether glucocorticoid dexamethasone influences AHR-mediated induction of CYP1A1 enzyme in the JEG-3 cell line. We found that dexamethasone dose- and time-dependently suppresses CYP1A1 transactivation in gene reporter assays, CYP1A1 mRNA induction, and upregulation of 7-ethoxyresorufin-O-deethylase (EROD) activity by 3-methylcholanthrene (MC) and 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in JEG-3 cells. Co-transfection of JEG-3 cells with glucocorticoid receptor (GR) expression construct and treatment with dexamethasone abolished the effect of MC on CYP1A1 promoter construct in transient transfection gene reporter assays. RU486, a GR antagonist, suppressed the effect of dexamethasone on MC-induced transactivation of AHR responsive reporter constructs. We also found that dexamethasone stimulates both ligand-dependent and ligand-independent degradation of AHR but not of aryl hydrocarbon receptor nuclear translocator (ARNT) protein in JEG-3 cells. In experiments with proteasome inhibitors MG132 and bortezomib, we found that the degradation is not sensitive to proteasome inhibition in JEG-3. We can conclude that dexamethasone suppresses AHR-mediated CYP1A1 induction in JEG-3 cells through the unique mechanism of AHR-GR crosstalk, which involves accelerated degradation of AHR.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc14050788
003      
CZ-PrNML
005      
20140410114752.0
007      
ta
008      
140401s2013 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.toxlet.2013.09.014 $2 doi
035    __
$a (PubMed)24091107
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Stejskalova, Lucie
245    10
$a Dexamethasone accelerates degradation of aryl hydrocarbon receptor (AHR) and suppresses CYP1A1 induction in placental JEG-3 cell line / $c L. Stejskalova, A. Rulcova, R. Vrzal, Z. Dvorak, P. Pavek,
520    9_
$a The JEG-3 choriocarcinoma cell line has been proposed as a model cell line of human placental trophoblast for induction studies via aryl hydrocarbon receptor (AHR). We examined whether glucocorticoid dexamethasone influences AHR-mediated induction of CYP1A1 enzyme in the JEG-3 cell line. We found that dexamethasone dose- and time-dependently suppresses CYP1A1 transactivation in gene reporter assays, CYP1A1 mRNA induction, and upregulation of 7-ethoxyresorufin-O-deethylase (EROD) activity by 3-methylcholanthrene (MC) and 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in JEG-3 cells. Co-transfection of JEG-3 cells with glucocorticoid receptor (GR) expression construct and treatment with dexamethasone abolished the effect of MC on CYP1A1 promoter construct in transient transfection gene reporter assays. RU486, a GR antagonist, suppressed the effect of dexamethasone on MC-induced transactivation of AHR responsive reporter constructs. We also found that dexamethasone stimulates both ligand-dependent and ligand-independent degradation of AHR but not of aryl hydrocarbon receptor nuclear translocator (ARNT) protein in JEG-3 cells. In experiments with proteasome inhibitors MG132 and bortezomib, we found that the degradation is not sensitive to proteasome inhibition in JEG-3. We can conclude that dexamethasone suppresses AHR-mediated CYP1A1 induction in JEG-3 cells through the unique mechanism of AHR-GR crosstalk, which involves accelerated degradation of AHR.
650    _2
$a receptory aromatických uhlovodíků - jaderný translokátor $x genetika $x metabolismus $7 D051784
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a cytochrom P-450 CYP1A1 $x antagonisté a inhibitory $x genetika $x metabolismus $7 D019363
650    _2
$a dexamethason $x farmakologie $7 D003907
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a reportérové geny $7 D017930
650    _2
$a glukokortikoidy $x farmakologie $7 D005938
650    _2
$a lidé $7 D006801
650    _2
$a methylcholanthren $x toxicita $7 D008748
650    _2
$a placenta $x účinky léků $x metabolismus $7 D010920
650    _2
$a těhotenství $7 D011247
650    _2
$a messenger RNA $x genetika $x metabolismus $7 D012333
650    _2
$a interakce mezi receptory a ligandy $7 D020239
650    _2
$a receptory aromatických uhlovodíků $x metabolismus $7 D018336
650    _2
$a receptory glukokortikoidů $x antagonisté a inhibitory $x genetika $x metabolismus $7 D011965
650    _2
$a polychlorované dibenzodioxiny $x toxicita $7 D000072317
650    _2
$a aktivace transkripce $7 D015533
650    _2
$a upregulace $7 D015854
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Rulcova, Alice $u -
700    1_
$a Vrzal, Radim $u -
700    1_
$a Dvorak, Zdenek $u -
700    1_
$a Pavek, Petr $u -
773    0_
$w MED00004537 $t Toxicology letters $x 1879-3169 $g Roč. 223, č. 2 (2013), s. 183-91
856    41
$u https://pubmed.ncbi.nlm.nih.gov/24091107 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20140401 $b ABA008
991    __
$a 20140410114842 $b ABA008
999    __
$a ok $b bmc $g 1017924 $s 849368
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2013 $b 223 $c 2 $d 183-91 $i 1879-3169 $m Toxicology letters $n Toxicol Lett $x MED00004537
LZP    __
$a Pubmed-20140401

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...